NYSE:RCUS Arcus Biosciences (RCUS) Stock Price, News & Analysis $16.77 +0.28 (+1.70%) (As of 09/19/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Arcus Biosciences alerts: Email Address About Arcus Biosciences Stock (NYSE:RCUS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Arcus Biosciences alerts:Sign Up Key Stats Today's Range$16.65▼$17.3150-Day Range$13.69▼$17.9952-Week Range$12.95▼$20.60Volume511,551 shsAverage Volume721,296 shsMarket Capitalization$1.53 billionP/E RatioN/ADividend YieldN/APrice Target$35.71Consensus RatingBuy Company OverviewArcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.Read More… Do NOT Day Trade (Do THIS instead) (Ad)Forget day trading (especially in markets like these). Trade OVERNIGHT instead! I've uncovered a shocking way to take 100% certain events (mandated by the U.S. Government)...Check Out The Data NOW Arcus Biosciences Stock Analysis - MarketRank™See Top Rated MarketRank™ StocksOverall MarketRank™: 68th PercentileArcus Biosciences scored higher than 68% of companies evaluated by MarketBeat, and ranked 368th out of 1,007 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.6 / 5Analyst RatingBuy Consensus RatingArcus Biosciences has received a consensus rating of Buy. The company's average rating score is 3.13, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageArcus Biosciences has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Arcus Biosciences' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Arcus Biosciences are expected to decrease in the coming year, from ($3.03) to ($4.64) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Arcus Biosciences is -5.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arcus Biosciences is -5.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArcus Biosciences has a P/B Ratio of 2.72. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Arcus Biosciences' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted13.83% of the float of Arcus Biosciences has been sold short.Short Interest Ratio / Days to CoverArcus Biosciences has a short interest ratio ("days to cover") of 9.9.Change versus previous monthShort interest in Arcus Biosciences has recently decreased by 3.30%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldArcus Biosciences does not currently pay a dividend.Dividend GrowthArcus Biosciences does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted13.83% of the float of Arcus Biosciences has been sold short.Short Interest Ratio / Days to CoverArcus Biosciences has a short interest ratio ("days to cover") of 9.9.Change versus previous monthShort interest in Arcus Biosciences has recently decreased by 3.30%, indicating that investor sentiment is improving. News and Social Media2.4 / 5News Sentiment0.38 News SentimentArcus Biosciences has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Arcus Biosciences this week, compared to 4 articles on an average week.Search InterestOnly 1 people have searched for RCUS on MarketBeat in the last 30 days. This is a decrease of -83% compared to the previous 30 days.MarketBeat Follows3 people have added Arcus Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Arcus Biosciences insiders have not sold or bought any company stock.Percentage Held by Insiders12.30% of the stock of Arcus Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions92.89% of the stock of Arcus Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Arcus Biosciences' insider trading history. Receive RCUS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arcus Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address RCUS Stock News HeadlinesBarclays Gives a Buy Rating to Arcus Biosciences (RCUS)September 16, 2024 | markets.businessinsider.comHold Rating on Arcus Biosciences Amid TIGIT Inhibitor UncertaintiesSeptember 16, 2024 | markets.businessinsider.comWho are Nvidia’s New Silent Partners?Nvidia knows it can’t stand still as AI continues to grow at an exponential rate. That’s why CEO Jensen Huang consistently has his company ahead of the curve when it comes to artificial intelligence. Nvidia’s added $2 trillion in market cap in 2024.September 20, 2024 | Weiss Ratings (Ad)Barclays Releases a Buy Rating on Replimune Group (REPL)September 16, 2024 | markets.businessinsider.comTruist Financial Remains a Buy on Mersana Therapeutics (MRSN)September 16, 2024 | markets.businessinsider.comTruist Financial Gives a Buy Rating to Merus (MRUS)September 13, 2024 | markets.businessinsider.comPrecision BioSciences Strengthens Senior Leadership Team Ahead of Anticipated PBGENE-HBV Clinical ExecutionSeptember 12, 2024 | finance.yahoo.comPrecision BioSciences to Participate in Upcoming H.C. Wainwright 26th Annual Global Healthcare ConferenceSeptember 4, 2024 | finance.yahoo.comSee More Headlines RCUS Stock Analysis - Frequently Asked Questions How have RCUS shares performed this year? Arcus Biosciences' stock was trading at $19.10 on January 1st, 2024. Since then, RCUS stock has decreased by 12.2% and is now trading at $16.77. View the best growth stocks for 2024 here. How were Arcus Biosciences' earnings last quarter? Arcus Biosciences, Inc. (NYSE:RCUS) announced its earnings results on Thursday, August, 8th. The company reported ($1.02) EPS for the quarter, hitting the consensus estimate of ($1.02). The business's revenue for the quarter was up 34.5% on a year-over-year basis. When did Arcus Biosciences IPO? Arcus Biosciences (RCUS) raised $99 million in an initial public offering on Thursday, March 15th 2018. The company issued 7,100,000 shares at $13.00-$15.00 per share. Citigroup, Goldman Sachs and Leerink Partners acted as the underwriters for the IPO. Who are Arcus Biosciences' major shareholders? Top institutional investors of Arcus Biosciences include Point72 Asset Management L.P. (2.01%), Dimensional Fund Advisors LP (1.63%), BNP PARIBAS ASSET MANAGEMENT Holding S.A. (0.82%) and Bank of New York Mellon Corp (0.44%). Insiders that own company stock include Gilead Sciences, Inc, Juan C Jaen, Terry J Rosen, Jennifer Jarrett, Robert C Goeltz II, Carolyn C Tang and Alexander Azoy. View institutional ownership trends. How do I buy shares of Arcus Biosciences? Shares of RCUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Arcus Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Arcus Biosciences investors own include Horizon Therapeutics Public (HZNP), BioDelivery Sciences International (BDSI), Pfizer (PFE), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), CRISPR Therapeutics (CRSP) and Gilead Sciences (GILD). Company Calendar Last Earnings8/08/2024Today9/20/2024Next Earnings (Estimated)11/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNYSE:RCUS CUSIPN/A CIK1724521 Webwww.arcusbio.com Phone(510) 694-6200FaxN/AEmployees500Year FoundedN/APrice Target and Rating Average Stock Price Target$35.71 High Stock Price Target$44.00 Low Stock Price Target$25.00 Potential Upside/Downside+113.0%Consensus RatingBuy Rating Score (0-4)3.13 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($3.11) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-307,000,000.00 Net Margins-100.81% Pretax Margin-99.60% Return on Equity-42.86% Return on Assets-20.90% Debt Debt-to-Equity RatioN/A Current Ratio5.14 Quick Ratio5.14 Sales & Book Value Annual Sales$247 million Price / Sales6.18 Cash FlowN/A Price / Cash FlowN/A Book Value$6.17 per share Price / Book2.72Miscellaneous Outstanding Shares90,953,000Free Float79,766,000Market Cap$1.53 billion OptionableOptionable Beta0.90 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report This page (NYSE:RCUS) was last updated on 9/20/2024 by MarketBeat.com Staff From Our PartnersAct by Friday, August 16th, to collect this 22% dividendLet's do a little math here... To double your money at a 3% rate of return, you would need around 23 years....Investors Alley | SponsoredWhy You Should NOT Trade This MarketYou'll be interested in our 5-Day Options Trading Challenge, starting September 23. So, what makes this dif...InvestorPlace | SponsoredThis Crypto Is Set to Explode in SeptemberWith thousands of cryptocurrencies out there, it's crucial to focus on the ONE that has the potential to make ...Crypto 101 Media | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredMust-Know for Trading OptionsOptions are becoming increasingly popular among investors – with demand hitting record highs for 3 years in a ...Unstoppable Prosperity | SponsoredDo NOT Day Trade (Do THIS instead)Forget day trading (especially in markets like these). Trade OVERNIGHT instead! I've uncovered a shockin...Monument Traders Alliance | SponsoredUnlock the Secret to Easy Wins with Iron CondorsDiscover the power of Iron Condor trades – a low-risk, high-reward strategy that allows you to profit consiste...Netpicks | SponsoredKamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppe...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcus Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arcus Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.